[6-acetyloxy-7-[(1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl)methyl]-1,3-benzoxazol-5-yl] acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: [6-acetyloxy-7-[(1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl)methyl]-1,3-benzoxazol-5-yl] acetate
• 化学式: C₂₆H₃₃NO₅
• 分子量: 439.5
• InChiKey: LBTUMRYFDFRELU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Use of sesquiterpene derivative
  申请人：KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION

  公开号：US10918625B2

  公开（公告）日：2021-02-16

  The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.

  本公开涉及倍半萜衍生物的一种新用途，更具体地说，涉及一种用于预防、改善或治疗由眼部血管渗漏引起的黄斑变性或黄斑水肿的组合物，该组合物含有本公开化学式 1 所代表的倍半萜衍生物化合物或其药学上可接受的盐作为活性成分。市场上与眼内疾病相关的治疗药物应直接注射到玻璃体腔内，因此会引起疼痛和副作用，而本公开的倍半萜衍生物化合物可通过不同的给药途径（口服、腹腔注射等）给药到目标组织（眼睛），而非玻璃体腔内途径。因此，倍半萜衍生物化合物不受给药途径的限制，可提供极佳的治疗效果。
• NOVEL USE OF SESQUITERPENE DERIVATIVE
  申请人：KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION

  公开号：US20190290617A1

  公开（公告）日：2019-09-26

  The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.